User:Reph-415: Difference between revisions
Content deleted Content added
mNo edit summary |
|||
| Line 71: | Line 71: | ||
{{Main|Norepinephrine reuptake inhibitor}} |
{{Main|Norepinephrine reuptake inhibitor}} |
||
{{Main|Norepinephrine releasing agent}} |
{{Main|Norepinephrine releasing agent}} |
||
* NET NAM / "partial releaser" : [[Α-Ethyltryptamine|αET]] (Emax ~ 75%) [https://doi.org/10.1016%2Fj.bmcl.2014.07.062] |
|||
* Nothing ? NET is not an interesting target apparently. |
|||
===DAT=== |
===DAT=== |
||
{{Main|Dopamine transporter}} |
{{Main|Dopamine transporter}} |
||
Revision as of 11:38, 17 August 2023
| |
| Names | |
|---|---|
| Other names
WHY
| |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Hi
I have tons of sexual intercourse all the time.[citation needed]
- Contributions
- How to
slap someone through the internetreport - This article about phenyltropanes looks like it was edited by someone high on phenyltropanes, check it out
to do
- Transistor ladder filter, diode ladder filter, OTA filter - or just expanding the voltage controlled filter article. - Currently in my sandbox !!
- Iboga alkaloid - Probably should be renamed to either "iboga-type alkaloid" or "substituted ibogamines". I submitted an attempt at making the article more detailed, and more sourced. I also (kind of) removed a weird attempt at promoting synthetic abominations that have little to do with iboga itself (18-MC).
- Iboluteine (ibogaine pseudoindoxyl) - An ibogaine oxydation product, analogous to the poorly studied opioid mitragynine pseudoindoxyl. Iboluteine and related metabolites possibly contribute to iboga's therapeutic effects. UPDATE : Unfortunately, research about iboga and its alkaloids has come to a crawling stop because of insane anti-drug propaganda from france and north america.
List of non-hallucinogenic 5-HT2A agonists
Tryptamines
- Serotonin
- Baeocystin, Norbaeocystin
- O-4310
- 6-Fluoro-DET
- Tabernanthalog
- PHA-57378
- PNU-22394
- Lisuride (ergoline)
- PNU-181731 (isotryptamine)
- AAZ-A-154 (isotryptamine)
Mescaline analogs
- 2,5-dimethoxy-phenethylamine (2C-H)
- 2,5-dimethoxyamphetamine (2,5-DMA or DOH)
- 2,5-dimethoxy-phenylisobutylamine (4C-H)
- 2,5-dimethoxy-4-fluorophenethylamine (2C-F)
- 2,5-dimethoxy-4-fluoroamphetamine (DOF)
- 2,5-dimethoxy-4-phenylisobutylamine (4C-F)
Others
List of atypical monoamine transporter ligands
There are many similar and/or contradicting hypotheses about monoamine transporter binding sites, here are some of them.
SERT
- SERT NAMs : paroxetine and escitalopram [1] (see allosteric serotonin reuptake inhibitor)
- SERT NAM / "partial releaser" : 4-Trifluoromethyl-Methcathinone (4-TFMMC) [2] CID:71550921
- SERT PAM / "reuptake enhancer" : tianeptine (putative)
- SERT PAM / "reuptake enhancer" : compound 7a [3] CID:71462111
NET
DAT
- Difluoropine, "inward-facing" reuptake inhibitor
- Vanoxerine, "inward-facing" reuptake inhibitor
- Modafinil, "inward-facing" reuptake inhibitor
- SoRI-20041, "antagonist-like" reuptake inhibitor that, counterintuitively, doesn't antagonize dextroamphetamine-mediated (transporter-mediated) dopamine release.
Others
- Selegiline, (-)-PPAP, and (-)-BPAP, "monoamine release enhancers"
- PCP and RTI-4793-14 bind to an allosteric modulator site on monoamine transporters : PCP site 2